Xilio Therapeutics
37 hedge funds and large institutions have $25.4M invested in Xilio Therapeutics in 2025 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 5 increasing their positions, 5 reducing their positions, and 9 closing their positions.
37% more capital invested
Capital invested by funds: $18.6M → $25.4M (+$6.82M)
33.12% more ownership
Funds ownership: 42.55% → 75.67% (+33%)
22% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 9
3% more funds holding
Funds holding: 36 → 37 (+1)
0% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 5
40% less funds holding in top 10
Funds holding in top 10: 5 → 3 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
+$4.44M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$3M |
| 3 |
BCLSI
Bain Capital Life Sciences Investors
Boston,
Massachusetts
|
+$2.11M |
| 4 |
SCM
Sio Capital Management
New York
|
+$1.6M |
| 5 |
SC
Stempoint Capital
New York
|
+$1.52M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Squarepoint
New York
|
-$277K |
| 2 |
TOCUITCONY
Trustees of Columbia University in the City of New York
New York
|
-$210K |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
-$168K |
| 4 |
Morgan Stanley
New York
|
-$91.6K |
| 5 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$44.1K |
XLO Hedge Fund Activity: Q4 2025 in Review
37 of the 8,280 institutional investors tracked by Wall St. Rank reported a position in Xilio Therapeutics (XLO) for Q4 2025, worth a combined $25.4M — up 37% from $18.6M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new XLO positions and 9 closed out — a net gain of 2 holders — while 5 added to existing stakes and 5 trimmed.
The largest buyer was Frazier Life Sciences Management, opening a new position worth an estimated $4.44M. The largest seller was Squarepoint, exiting entirely with an estimated $277K sold.
- 37 institutional investors held Xilio Therapeutics (XLO) as of Q4 2025, up from 36 in Q3 2025.
- Funds reported $25.4M of Xilio Therapeutics stock for Q4 2025, up 37% quarter-over-quarter.
- 11 funds opened new Xilio Therapeutics positions in Q4 2025 and 9 closed out, a net change of +2 holders.
- The largest Xilio Therapeutics buyer in Q4 2025 was Frazier Life Sciences Management, an estimated $4.44M added.
- The largest Xilio Therapeutics seller in Q4 2025 was Squarepoint, an estimated $277K sold.
Based on aggregated 13F filings for Q4 2025.